Peptide for preventing or treating inflammatory diseases and use thereof
The present invention relates to a peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
1. A peptide consisting of the amino acid sequence of SEQ ID NO: 1, wherein the N- or C-terminal of the peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG) group.
2. A method for treating rheumatoid arthritis, comprising the step of administering a composition comprising a pharmaceutically effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the peptide as an active ingredient to a subject having rheumatoid arthritis.
3. The method of claim 2 , wherein the N- or C-terminal of the peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG) group.
4. The method of claim 2 , wherein the composition inhibits generation of inflammatory cytokine.
5. The method of claim 2 , wherein the composition further comprises: a pharmaceutically acceptable carrier.
6. The method of claim 2 , wherein the composition is simultaneously, separately or sequentially administered with other anti-inflammatory agents in addition to the peptide consisting of the amino acid sequence of SEQ ID NO: 1 or the polynucleotide encoding the peptide.
7. The method of claim 2 , wherein the composition is formulated for oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, intradermal administration, or topical administration.